Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

开始日期2023-10-03

申办/合作机构

DalCor Pharmaceuticals Canada, Inc.初创企业

NCT04676867

/ Completed临床2期

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

开始日期2021-01-11

申办/合作机构

DalCor Pharmaceuticals Canada, Inc.初创企业

[+1]

NCT02525939

/ Completed临床3期

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

开始日期2016-04-01

申办/合作机构

DalCor Pharmaceuticals Canada, Inc.初创企业

[+2]

100 项与达塞曲匹相关的临床结果

登录后查看更多信息

100 项与达塞曲匹相关的转化医学

登录后查看更多信息

100 项与达塞曲匹相关的专利（医药）

登录后查看更多信息

296

项与达塞曲匹相关的文献（医药）

2024-11-01·Journal of Computational Biophysics and Chemistry

Molecular Docking, Quantum Mechanics and Molecular Dynamics Simulation of Anti-CAD Drugs Against High-Risk Xanthine Dehydrogenase Variants Associated with Oxidative Stress Pathways

作者: Ahmed, Shiek S. S. J. ; Ahmad, Sheikh F. ; Emran, Talha Bin ; Janakiraman, V. ; Attia, Sabry M. ; Sudhan, M.

Xanthine dehydrogenase (XDH) contributes significantly to generating reactive oxygen species in coronary artery disease (CAD). XDH has been proposed as a therapeutic target, but its genetic variants could affect protein structure and drug response. We aimed to assess protein structure modification occur due to genetic variants and to screen 215 CAD drugs for their utility in personalized CAD treatment against the XDH variants. A series of computational methods were implemented to identify pathogenic variants that cause XDH structure instability localized at the con served regions contributing to functional significance. Then, the XDH structures with the pathogenic variants were modeled using two different approaches to select the best models for docking with the CAD drugs. Finally, the stability of the docked complexes and their ability to transfer electrons were evaluated using molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculation. Among 751 variants examined; R149C and Q919R showed high pathogenicity, localized in conserved regions could alter protein structure and function. Further, docking of CAD drugs against XDH (native, R149C and Q919R) showed vericiguat with higher affinity, ranging from −7.95 kcal/mol to −10.41 kcal/mol, than the well-known XDH inhibitor (febuxostat, −5.73 kcal/mol to −8.35 kcal/mol). This indicates that vericiguat will be effective in CAD treatment, regardless of the XDH variants. Additionally, MD simulation and QM/MM confirmed vericiguat stability and electron transfer ability to form hydrogen bonds with the XDH protein. In conclusion, vericiguat will be beneficial for the personalized treatment of CAD by inhibiting XDH variants. Additional clinical studies are necessary to confirm our findings.

2024-06-01·Journal of the American College of Cardiology

Enhancing HDL Function to Prevent Atherothrombosis

作者: Finn, Aloke V

THis study is about Enhancing HDL Function to Prevent Atherothrombosis.Despite advances in our understanding of the pathogenesis of acute myocardial infarction (MI), atherosclerotic coronary artery disease remains a leading cause of death in the world.Here it was discussed about the deposition of cholesterol in the form of lipoproteins within the walls of blood vessels leads to the development of atherosclerotic plaques.Death and morbidity from atherosclerotic heart disease have been diminishing largely because of better risk factor management including control of low-d. lipoprotein cholesterol(LDL-C) levels.However,patients with established atherosclerotic cardiovascular (CV) disease are at very high risk for recurrent events, including MI, stroke,and death even on LDL-C lowering therapies.Epidemiol. studies have shown a strong inverse correlation between circulating high-d. lipoprotein (HDL) cholesterol and the risk of ischemic heart disease.The main function of HDL is to scavenge excess cholesterol from peripheral tissues back to the liver through a process called reverse cholesterol transport.However, the development of new therapies that increase plasma HDL levels has proven challenging, highlighted by the failure of torc etrapib and dalcetrapib, 2 different inhibitors of cholesteryl ester transfer protein, and of extended release niacin in recent clin. trials.Last, would CSL112 be more effective in the early stages of atherosclerosis where plaque necrosis is less advanced (pathol. intimal thickening and early fibroatheroma) and lipid particle (oxidized LDL) are attached to proteoglycan hyaluronan and versican.Whereas treating patients with late-stage disease remains an important and worthy goal, enhancing cholesterol efflux at the earliest stages of disease in those with known impaired function may have a larger effect on plaque growth and progression.To date the field is littered with mostly failed trials to improve CV outcomes in patients treated with guideline driven LDL-lowering therapies..Nonetheless, agents with different mechanisms for preventing atherothrombosis beyond LDL-C lowering are needed to further reduce cardiovascular events.This biol. underpinning behind HDL-enhancing therapies is sound but further work is needed to explore any potential benefits.

2023-12-05·Journal of the American Heart Association

Interventions to Attenuate Cardiovascular Calcification Progression: A Systematic Review of Randomized Clinical Trials

Review

作者: Smith, Edward R. ; Tiong, Mark K. ; Tan, Sven‐Jean ; Toussaint, Nigel D. ; Murali, Shashank

BackgroundCardiovascular calcification, characterized by deposition of calcium phosphate in the arterial wall and heart valves, is associated with cardiovascular morbidity and mortality and is commonly seen in aging, diabetes, and chronic kidney disease. Whether evidence‐based interventions could significantly attenuate cardiovascular calcification progression remains uncertain.Methods and ResultsWe conducted a systematic review of randomized controlled trials involving interventions, compared with placebo, another comparator, or standard of care, to attenuate cardiovascular calcification. Included clinical trials involved participants without chronic kidney disease, and the outcome was cardiovascular calcification measured using radiological methods. Quality of evidence was determined by the Cochrane risk of bias and Grading of Recommendations, Assessment, Development, and Evaluations assessment. Forty‐nine randomized controlled trials involving 9901 participants (median participants 104, median duration 12 months) were eligible for inclusion. Trials involving aged garlic extract (n=6 studies) consistently showed attenuation of cardiovascular calcification. Trials involving 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (n=14), other lipid‐lowering agents (n=2), hormone replacement therapies (n=3), vitamin K (n=5), lifestyle measures (n=4), and omega‐3 fatty acids (n=2) consistently showed no attenuation of cardiovascular calcification with these therapies. Trials involving antiresorptive (n=2), antihypertensive (n=2), antithrombotic (n=4), and hypoglycemic agents (n=3) showed mixed results. Singleton studies involving salsalate, folate with vitamin B6 and 12, and dalcetrapib showed no attenuation of cardiovascular calcification. Overall, Cochrane risk of bias was moderate, and the Grading of Recommendations, Assessment, Development, and Evaluations assessment for a majority of analyses was moderate certainty of evidence.ConclusionsCurrently, there are insufficient or conflicting data for interventions evaluated in clinical trials for mitigation of cardiovascular calcification. Therapy involving aged garlic extract appears most promising, but evaluable studies were small and of short duration.

项与达塞曲匹相关的新闻（医药）

2024-07-30

·药融圈

多家大药厂折戟，成功率0%高难度靶点，荷兰小型biotech能否率先破局？

▲8月15-16日苏州2024生物医药创新者峰会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。心血管疾病是全球的主要死亡原因，根据药融咨询《中国心血管系统药物分析报告》，近30年，全球心血管疾病（CVD）患病人数几乎翻了一番，从1990年的2.7亿例增长到2019年的5.23亿例，人口增长和老龄化是心血管疾病患病人数增长的主要驱动因素。其中，动脉粥样硬化是心脏病发作、中风和周围血管疾病的主要原因，动脉粥样硬化性心血管疾病（ASCVD）最重要的危险因素之一是高胆固醇血症，即体内LDL-C（低密度脂蛋白胆固醇）水平升高。他汀类药物是一类降脂药物，是目前治疗高危心血管病伴高胆固醇患者的标准治疗药物，然而，相当比例的高胆固醇患者单独使用他汀类药物治疗不能将LDL-C降至理想水平。虽然目前市场上有非他汀类药物治疗方案，例如PCSK9（前蛋白转化酶枯草溶菌素9）抑制剂作为降脂治疗的新选择，但其价格昂贵且为注射制剂，限制广泛使用。因此，鉴于庞大的疾病人群，对于强效、经济和方便的低密度脂蛋白降低疗法作为他汀类药物的辅助治疗方面，依然存在着巨大的未满足需求。药融云数据www.pharnexcloud.com显示，NewAmsterdam Pharma（NASDAQ：NAMS，以下简称NAP）是一家总部位于荷兰纳尔登的临床阶段生物制药公司，其使命是改善代谢性疾病患者的治疗，这些疾病目前批准的疗法尚未足够成功或耐受不良。 NAP正在研究Obicetrapib，一种口服、低剂量和每日一次的CETP（胆固醇酯转运蛋白）抑制剂，作为首选的LDL-C（低密度脂蛋白胆固醇）降低疗法，用于高危心血管疾病患者的最大耐受剂量他汀类药物治疗的辅助治疗。同时，该公司认为CETP抑制有可能通过降低阿尔茨海默氏症、2型糖尿病等疾病的进展风险，从而在其他适应症中发挥作用。成功率0%的高难度靶点 CETP（胆固醇酯转运蛋白）是一种由肝脏分泌的血浆糖蛋白，介导胆固醇酯和甘油三酯在高密度脂蛋白（HDL）、极低密度脂蛋白（VLDL）和低密度脂蛋白（LDL）颗粒之间的双向转运。1980年代中期，日本首次报道了CETP（胆固醇酯转运蛋白）活性遗传缺陷及其与改善脂质成分（降低LDL-C和增加HDL-C），减少早发性动脉粥样硬化的关系。其实针对CETP（胆固醇酯转运蛋白）抑制剂，早已有几家大药厂开展过大规模研究，CETP曾被认为是心血管领域新的重磅靶点，但是针对这一靶点，依然没有药物上市，可见其开发难度之高。最先开启3期临床研究的CETP抑制剂是辉瑞的torcetrapib，但研究显示该药物增加了心血管事件和死亡的风险，最终不得不提前终止开发，而辉瑞已在该药物研发上斥资了8亿美元，torcetrapib成为了辉瑞研发史上最惨痛的失败之一。后来发现torcetrapib具有结构相关的脱靶效应，导致血压升高，醛固酮、类固醇和内皮素-1水平升高，以及电解质异常。有了前车之鉴，后来进入临床的几款CETP抑制剂均没有显示出脱靶效应特征，且具有良好的安全性，然而却因为没有达到预期疗效而终止了研究，包括罗氏的dalcetrapib（引进自日本烟草）和礼来的evacetrapib。2017年10月，默沙东宣布将不再寻求其CETP抑制剂anacetrapib的监管批准，理由是该药物的临床研究结果不支持上市申请，在3期研究中，anacetrapib仅使心脏病发作及死亡风险降低9%，同时，该药物会在脂肪组织中积聚，这使得商业化前景更不明朗。同一年，安进也宣布停止其CETP抑制剂AMG 899（Obicetrapib）的内部开发，并寻求对外许可机会，业界推测极大可能是受到了默沙东放弃递交anacetrapib上市申请的影响。曾经的最后一个CETP抑制剂并未退场安进的AMG 899（Obicetrapib）前称为TA-8995，由安进在2015年以15.5亿美元收购荷兰生物技术公司Dezima Pharma而得。根据药融云数据www.pharnexcloud.com提供线索，TA-8995由日本田边三菱制药株式会社（MTPC）最早进行研发，后授权给了Dezima Pharma，MTPC则保留了在亚洲某些地区（包括日本）的开发和商业化权利。截图自药融云数据库而本文的主角NewAmsterdam Pharma（以下简称NAP）在2020年从安进手中重新收购了Dezima Pharma，获得了Obicetrapib。NAP由荷兰阿姆斯特丹大学学术医学中心血管医学系的名誉医学教授John Kastelein博士和风险投资公司Forbion于2019年创立。而Dezima Pharma也是由John Kastelein教授于2012年创立，并受到了Forbion的资助。当2017年安进宣布停止Obicetrapib的内部开发并寻求对外许可之时，Forbion认为这种药物可以解决非常大的未满足医疗需求，并开始与安进公司对话，以继续开发该资产。为此Forbion与John Kastelein教授联合成立了NAP，目前Kastelein教授担任该公司的首席科学官。 2021年1月，NAP完成了1.96亿美元（1.6亿欧元）的A轮融资，由Forbion、Morningside Ventures和Ascendant BioCapital领投。从而支持Obicetrapib的3期临床开发。（相关阅读：1.96亿美元A轮融资，用于CETP抑制剂III期临床） 2022年6月，NAP与意大利制药公司美纳里尼集团签订了Obicetrapib在欧洲商业化的独家许可协议，同时保留在世界其他地区商业化Obicetrapib的所有权利（如果获得批准），以及开发某些形式的Obicetrapib用于治疗其他疾病（如阿尔茨海默病）的权利。（相关阅读：首付超1.4亿欧元，美纳里尼斩获心血管疾病新药obicetrapib） 2022年7月，NAP宣布与特殊目的收购公司Frazier Lifesciences Acquisition Corporation达成合并协议，合并后的新公司在纳斯达克上市，股票代码为“NAMS”。研究重点的转变最初在开发用于降低ASCVD（动脉粥样硬化性心血管疾病）风险的CETP抑制剂时，大家关注的重点在于其提高HDL-C（高密度脂蛋白胆固醇，俗称“好胆固醇”）的能力，但是现在CETP抑制剂的开发重点已确定为降低LDL-C（低密度脂蛋白胆固醇，俗称“坏胆固醇”）、非HDL-C和ApoB（载脂蛋白B）的能力，并受到了动物模型、观察性队列、孟德尔随机化研究、随机对照试验和大型荟萃分析等综合证据的支持。根据NAP披露，与先前的几款CETP抑制剂相比，Obicetrapib具有内在特性，如可电离特性，且亲脂性显著降低，因此该公司认为与其他CETP抑制剂相比，Obicetrapib作为候选药物具有更有利的物理、药代动力学和生物制药特性。将Obicetrapib与等效剂量的anacetrapib和evacetrapib相比，以及10mg剂量的Obicetrapib与100mg剂量的anacetrapib相比，Obicetrapib被证明可以更大程度地降低CETP活性。在NAP开展2b期ROSE试验中，在高强度他汀类药物的基础上，10 mg剂量Obicetrapib治疗显示LDL-C较基线降低51%；在2期ROSE2试验中，10 mg剂量Obicetrapib联合10 mg剂量依泽替米贝治疗显示LDL-C较基线降低了63%，研究达到了主要和次要终点。在评价Obicetrapib作为单药疗法或与10 mg依泽替米贝联用的5项2期临床研究（TULIP、ROSE、OCEAN、ROSE2以及在日本的2b期试验）中，均观察到LDL-C水平具有统计学意义的降低，其副作用的频率和严重程度与安慰剂相似。在NAP迄今开展的临床试验中，Obicetrapib在800多名血脂异常的患者中显示出良好耐受性。鉴于研究观察到的LDL-C降低能力和安全性，NAP选择10mg剂量的Obicetrapib开展3期临床研究，并设计了专门的心血管获益研究（CVOT），旨在避免以前CETP抑制剂研究方案的缺点，并期望最终能够满足那些尽管接受目前最佳降脂治疗但LDL-C水平仍然升高的ASCVD（动脉粥样硬化性心血管疾病）和/或HeFH（家族性高胆固醇血症）患者的未满足治疗需求。此外，NAP认为，Obicetrapib的口服递送、低剂量、化学特性和耐受性使其非常适合于联合治疗。该公司也正在开发Obicetrapib10 mg + 依泽替米贝10 mg的固定剂量组合。单药、联合疗法3期临床推进中目前，NAP围绕Obicetrapib作为单药疗法开展了2项关键3期临床试验，即BROADWAY和BROOKLYN，以评估Obicetrapib作为最大耐受剂量降脂疗法的辅助疗法，以潜在地进一步降低ASCVD或HeFH患者的LDL-C水平。这两项研究已在2023年完成入组，BROADWAY研究随机分配了超过2500名患者，BROOKLYN研究随机分配了超过350名患者。该公司预计将分别于2024年Q3和Q4公布BROOKLYN研究和BROADWAY研究的顶线数据。 2022年3月，NAP启动了3期CVOT（心血管获益）研究PREVAIL，旨在评估Obicetrapib减少MACE（主要心血管事件，包括心血管疾病死亡、非致死性心肌梗死、非致死性中风和非选择性冠状动脉重建术）发生率的潜力，该研究于2024年4月完成患者入组，随机分配了超过9500名患者，预计将于2026年公布顶线数据。对于联合疗法，NAP基于2期ROSE2临床试验的积极结果与经验，以及在2023年上半年完成的Obicetrapib 10 mg + 依泽替米贝10 mg固定剂量组合与原型药物的生物等效性实验，公司在2024年3月启动了关键3期临床试验TANDEM，以评估Obicetrapib 10 mg + 依泽替米贝10 mg固定剂量组合作为饮食控制和最大耐受剂量降脂疗法的辅助治疗，潜在地进一步降低HeFH、ASCVD或ASCVD高风险患者LDL（低密度脂蛋白）水平的能力。该研究计划在美国招募约400名基线LDL-C≥70 mg/dL的患者，预计将在2025年Q1公布顶线数据。NAP的目标是在递交Obicetrapib单药的NDA后不久，再递交一个固定剂量组合的NDA申请。 NAP计划在美国、欧盟、日本、中国和英国寻求Obicetrapib的批准。药融云数据www.pharnexcloud.com显示，Obicetrapib在国内正同步进行3期临床研究，主要临床机构为北京大学第一医院。截图自药融云数据库阿尔茨海默氏症、糖尿病的尝试 NAP认为，CETP抑制也可能通过潜在地降低诸如阿尔茨海默氏症或糖尿病等疾病的发展风险，在其他适应症中发挥作用。有证据表明，大脑中胆固醇的积累是阿尔茨海默氏病的前兆。例如，缺乏CETP基因的啮齿类动物对阿尔茨海默氏病有抵抗力。在早期的临床前研究中，当人类的CETP基因被敲入小鼠，小鼠大脑中的胆固醇含量增加了25%；当与淀粉样前体蛋白（假设是阿尔茨海默病的驱动因素）的基因结合时，在双转基因小鼠中观察到患类似阿尔茨海默病的疾病的风险大大增加。在一项临床前研究中，该公司观察到CETP抑制促进了大脑中胆固醇的清除并改善了认知能力。 NAP于2022年初开始了一项2a期开放标签和单臂试验，用于早期阿尔茨海默病和载脂蛋白E4（ApoE4）发生自然变异的患者，以评估Obicetrapib的药效学和药代动力学效应、安全性和耐受性，共13例患者给予Obicetrapib 10 mg，随访24周。2023年9月，该公司宣布了该试验初步数据，与基线水平相比，患者脑脊液中24-羟基胆固醇和27-羟基胆固醇的水平分别降低了11%和12%。此外，患者血浆中Aβ42/40比值较基线增加了8%，pTau181水平稳定。以往的CETP抑制曾在3期CVOT（心血管获益）研究中显示出抗糖尿病益处，若Obicetrapib也能显示出抗糖尿病益处，它将区别于目前的治疗方案，特别是与他汀类药物相比（他汀类药物可能致新发糖尿病的风险存在剂量依赖性）。NAP计划开展临床前研究以探索Obicetrapib治疗糖尿病患者的潜力，并已经将新发2型糖尿病作为Obicetrapib的3期CVOT研究PREVAIL的一个终点。财务状况 2023全年，NAP公司总收入为1410万美元，而上一年同期为1.027亿美元，这一下降主要是由于2022年收到了美纳里尼的预付款；2023年R&D费用为1.594亿美元，上一年同期为8670万美元，这一增长主要与正在进行的3期临床试验有关；SG&A费用为3760万美元，上一年同期为1950万美元，主要是因为公司人员增长。2023全年净亏损为1.769亿美元，或每股亏损2.15美元。 2024年Q1，NAP公司总收入为140万美元，而2023年同期为860万美元，这一下降主要是由于去年同期获得了临床相关里程碑收入；第一季度R&D费用为4240万美元，而2023年同期为4040万美元；SG&A费用为1450万美元，而2023年同期为810万美元，这一增长主要是由于团队扩张等，以支持Obicetrapib的商业化推出（若获得批准）。第一季度净亏损为9380万美元，或稀释后每股亏损1.06美元。 2024年2月，NAP宣布以1.753亿美元公开发行普通股和预融资认股权证，截至2024年3月31日，NAP拥有4.811亿美元的现金。截至7月4日，该公司市值约为18亿美元。截止发稿前市值为15.52亿美元，每股17.25美元。结语从田边三菱最早研发TA-8995（Obicetrapib）开始，这一分子在多年间几经转手，目前正处于关键3期临床研究阶段。今年6月，美国专利及商标局为Obicetrapib颁发了第三代物质组合物专利，该专利将Obicetrapib的知识产权保护和排他性延长至2043年7月。NewAmsterdam Pharma能否借助前面几家大厂的经验与教训将Obicetrapib推向成功？业内对CETP抑制剂的研发热情会重燃吗？我们可以拭目以待。此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐参考： NMPA/CDE；药融云数据www.pharnexcloud.com； FDA/EMA/PMDA；相关公司公开披露（正文图片均来自企业官方，除非另有说明）； https://www.newamsterdampharma.com/； Kastelein, John J P et al. “Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.” Current atherosclerosis reports vol. 26,2 (2024): 35-44. doi:10.1007/s11883-023-01184-1； https://www.amgen.com/newsroom/press-releases/2015/09/amgen-to-acquire-privately-held-dezima-pharma； https://www.businesswire.com/news/home/20200825005160/en/NewAmsterdam-Pharma-Acquires-Obicetrapib-from-Amgen； https://www.prnasia.com/story/366920-1.shtml；等等 8月15日苏州国际博览中心C馆C102 新药创始人峰会会议日程 09:00-09:25 如何应对复杂的生物医药产业环境？（拟定，以会议现场为准）王兴利｜复星医药，执行总裁&创新药事业部联席CEO 09:25-09:50 跨越周期，承压下的中国Biotech公司还有哪些机会把握？（拟定，以会议现场为准）崔兴品｜华润医药集团，副总裁、华润三九医药董事 09:50-10:15 绕不开的商业化，Biotech公司该怎么看待商业化？（拟定，以会议现场为准）刘谦｜阿斯利康中国，副总裁 10:15-10:40 跨国公司视角：MNC在中国市场角色的转变 10:40-11:05 2024中国医药企业综合实力排行榜系列榜单发布杨建云｜药融云，副总经理 11:05-11:30 中国生物医药产业投资机会分析毛化｜沙利文，大中华区合伙人兼董事总经理 11:30-12:00 圆桌：中国Biotech公司未来突破点有哪些？ 1.被MNC并购，前提是准备好没？ 2.进入集采，创新药的想象力真的那么好？ 3.被国内大药企并购退出？ 4.抓住机会从Biotech到Biopharm? 5.以仿养创？怎么养？ 6.兼顾CRO业务获得现金流？卷得动吗？主持人：邓永奇｜凯复医药，CEO 王兴利｜复星医药，执行总裁&创新药事业部联席CEO 金方｜健康元，首席科学家刘谦｜阿斯利康中国，副总裁 12:00-13:30 午餐【中国新药的理性发展方向】论坛策划人&主持人：党群，真实生物，总裁 13:30-13:55 创新药是选FIC还是BIC？解决临床未满足需要是关键！党群｜真实生物，总裁 13:55-14:20 和誉医药FGFR抑制剂开发进展陈椎｜和誉医药，联合创始人兼CSO 14:20-14:45 细胞治疗产品动物药效评价曹保红｜美迪西，药理部副总裁 14:45-15:10 YAP/TEAD抑制剂的开发朱继东｜奕拓医药，CEO 15:10-15:35 浅谈“前药”的前世今生-长乘医药的前药研发宋钦辉｜长乘医药，CMO 15:35-16:00 慢乙肝功能性治愈创新药物的研究与开发张弛｜西安新通药物，副总经理 16:00-16:25 Delivery of Excellence - 递送引导的药物创新沈旺｜维眸生物，创始人、董事长兼CEO 扫码报名参会【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

2023-11-17

·SYNAPSE

What are CETP inhibitors and how do you quickly get the latest development progress?

CETP, or Cholesteryl Ester Transfer Protein, plays a crucial role in lipid metabolism within the human body. It facilitates the transfer of cholesteryl esters (CE) and triglycerides (TG) between high-density lipoproteins (HDL) and low-density lipoproteins (LDL). By promoting the exchange of lipids, CETP contributes to the redistribution of cholesterol and triglycerides among lipoprotein particles. This process is essential for maintaining a healthy lipid profile and preventing the accumulation of cholesterol in the arteries. Understanding the function of CETP has led to the development of pharmaceutical interventions aimed at modulating its activity to improve cardiovascular health. Currently, the main drugs for increasing HDL-C include fibrates, niacin, and Cholesteryl Ester Transfer Protein (CETP) inhibitors. Among them, CETP inhibitors are the most potent in elevating HDL-C levels, making them a recent focus of major pharmaceutical companies. CETP is a plasma glycoprotein synthesized by the liver, most of which circulates in combination with HDL. The primary function of CETP is to mediate the transfer of cholesterol from HDL to VLDL and LDL during the process of triacylglycerol exchange, and CETP inhibitors can block this transfer process, theoretically possessing anti-atherosclerosis effects and the ability to reduce cardiovascular risks. The first CETP inhibitor developed by Pfizer in 2006, Torcetrapib, significantly increased HDL-C in coronary disease patients by 72.1%, but paradoxically, this increase led to a rise in cardiovascular events and mortality risk. In 2012, Dalcetrapib, a CETP inhibitor developed by Roche, significantly increased HDL-C levels by 31% to 40% compared to baseline in acute coronary syndrome patients during the dal-OUTCOMES phase III trial with an average follow-up of 31 months. However, the benefits in the primary endpoint (a composite of coronary death, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest revival) were no better than the placebo group, and its development was also terminated. Lilly ceased development of its CETP inhibitor evacetrapib on October 12, 2015, and the prospects for Merck's anacetrapib are similarly bleak. However, research and development of CETP inhibitors have not stopped, with drugs such as BAY60-5521, JNJ-28545595, TA8895, and CKD519 gradually entering the preclinical development phase. Recent studies regarding the safety, tolerability, and pharmacodynamics of CKD-519 in a single ascending dose study with 40 healthy volunteers demonstrated that a single dose of CKD-519 (25 mg to 400 mg) significantly increased HDL-C levels without causing severe adverse events, nor causing an increase in blood pressure similar to that caused by Torcetrapib. Therefore, the issue that increasing HDL-C does not decrease cardiovascular events and mortality risk, as well as the future research direction for CETP inhibitors, have become recent points of discussion and research focus. How do they work?CETP inhibitors are a type of drug that target the cholesteryl ester transfer protein (CETP). CETP is a protein involved in the transfer of cholesterol esters between lipoproteins, such as high-density lipoprotein (HDL) and low-density lipoprotein (LDL). From a biomedical perspective, CETP inhibitors are designed to block the activity of CETP, thereby increasing the levels of HDL cholesterol and reducing the levels of LDL cholesterol. This mechanism is based on the understanding that higher levels of HDL cholesterol are associated with a lower risk of cardiovascular diseases, while elevated levels of LDL cholesterol are linked to an increased risk. By inhibiting CETP, these drugs aim to promote a favorable lipid profile and potentially reduce the risk of conditions like atherosclerosis, heart attacks, and strokes. However, it is important to note that the clinical efficacy and safety of CETP inhibitors are still being evaluated, and more research is needed to fully understand their potential benefits and risks. List of CETP InhibitorsThe currently marketed CETP inhibitors include: Ezetimibe/Pitavastatin CalciumDalcetrapibEvacetrapibObicetrapibObicetrapib/EzetimibeDRL-17822IcosabutateNST-1024CKD-508AnacetrapibFor more information, please click on the image below. What are CETP inhibitors used for?CETP inhibitors are approved indications include Hypercholesterolemia and Hyperlipoproteinemia Type II. For more information, please click on the image below to log in and search. How to obtain the latest development progress of CETP inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of CETP inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

2023-09-13

·GlobeNewswire-Health Care

DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round

MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Dal-GenE-2 (Dal-302), a phase III, double-blind, randomized placebo-controlled study, will evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction (MI) in approximately 2,000 patients with a documented recent acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene. “Following the dal-GenE trial results showing a potential benefit in a genetically defined patient population, we are pleased to have reached agreement with the FDA to conduct the Dal-GenE-2 confirmatory trial to support a potential new drug application (NDA) filing,” said Dr. Fouzia Laghrissi Thode, CEO of DalCor Pharmaceuticals. This confirmatory trial follows the results of the dal-GenE trial which showed a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and a 45% RRR in 1,200 patients in North America and confirmed the safety profile of dalcetrapib. “The AA genotype frequency is up to 20% in European populations and is higher than 40% in populations of African ancestery,” said Dr Eldrin F. Lewis, Chief of the Division of Cardiovascular Medicine at Stanford University, Professor of Cardiovascular Medicine, and Chair of the Dal-GenE-2 diversity committee. “With the relative risk reduction seen in North American patients in the dal-GenE study and the continued commitment to investigating the first potential pharmacogenetic precision medicine for patients with cardiovascular disease, we are pleased to partner with DalCor Pharmaceuticals in this confirmatory trial.” The Series D financing includes the participation of Fonds de Developpement Économique from the Québec government managed by Investissement Québec and Fonds Propres d’ Investissement Québec as well as current investors including Andes Growth, TB Pharma, Fonds de Solidarité FTQ, and CTI Life Sciences. “Québec’s life-sciences expertise is recognized worldwide. Our government is keen to support projects with the potential to generate meaningful spinoffs, like DalCor’s work on cardiovascular health,” said Pierre Fitzgibbon, Minister of Economy, Innovation and Energy, Minister Responsible for Regional Economic Development and Minister Responsible for the Montréal Region. “We are pleased to support DalCor in this round of financing so they can carry on development in precision medicine for cardiovascular disease,” said Guy LeBlanc, President, and CEO of Investissement Québec. “Their research can ultimately revolutionize their industry and reduce the number of cardiovascular events. Investissement Québec will keep supporting emerging young businesses to position Québec in key sectors of our economy, such as life sciences.”- - Notes: Dal-GenE-2: The primary objective of Dal-GenE-2 is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in 2,000 patients with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene. The trial is expected to start in Q3 2023 with an interim efficacy analysis in 2026, and completion anticipated in 2027. Dal-GenE: While the trial missed the primary endpoint, most likely due to the impact of the COVID-19 pandemic, the results show a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and 45% RRR in 1,200 patients in North America. These data support the further development of dalcetrapib. DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients. DalCor Pharmaceuticals holds the worldwide exclusive license to develop, manufacture and commercialise dalcetrapib, and holds the right to the genetic marker for use with dalcetrapib in patients with the AA genotype at variant rs1967309 in the ADCY9 gene. A companion diagnostic test, developed in conjunction with Roche Diagnostics, identifies patients with the ADCY9 AA genotype who may potentially benefit from dalcetrapib treatment. For more information, visit www.dalcorpharma.com.

临床3期引进/卖出

100 项与达塞曲匹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09708	达塞曲匹	-	DB12181

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠状动脉疾病	药物发现	斯洛伐克	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	以色列	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	加拿大	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	捷克	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	新西兰	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	瑞典	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	格林纳达	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	美国	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	法国	Hoffmann-La Roche, Inc.	2008-04-01
冠状动脉疾病	药物发现	荷兰	Hoffmann-La Roche, Inc.	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04676867 (CTgov)	临床2期	新型冠状病毒感染	227	Placebo (Placebo Tablets)	選選積獵衊淵淵憲簾夢(窪鬱範廠鏇憲簾獵廠網) = 選憲襯網鹹蓋觸範窪構醖選製襯糧築糧襯鬱製 (顧鬱觸淵積艱積簾鑰積, 壓夢窪廠構選蓋鏇衊夢 ~ 衊範鏇鏇鹹膚蓋鬱衊壓) 更多	-	2022-12-07
				Dalcetrapib (900 mg Dose)	選選積獵衊淵淵憲簾夢(窪鬱範廠鏇憲簾獵廠網) = 鑰顧鬱鹹選蓋範餘繭選醖選製襯糧築糧襯鬱製 (顧鬱觸淵積艱積簾鑰積, 齋淵壓淵鏇觸積糧鹽膚 ~ 願願築鹹顧鏇網選構鏇) 更多
NCT02525939 (dal-GenE, CTgov)	临床3期	急性冠状动脉综合征 \| Acrocallosal综合征	6,147	Placebo (Placebo)	製築廠鹹艱獵膚製鑰鏇(鏇鬱糧膚餘廠積選窪蓋) = 鹹鏇鏇構顧衊鬱願壓鏇夢遞鬱網範遞顧蓋範鑰 (鹹膚繭淵築繭窪夢鬱憲, 網顧構獵淵範齋壓襯壓 ~ 獵廠壓鹹鬱選遞餘淵鹽) 更多	-	2022-10-12
				dalcetrapib (Dalcetrapib)	製築廠鹹艱獵膚製鑰鏇(鏇鬱糧膚餘廠積選窪蓋) = 憲夢齋艱糧憲憲夢膚衊夢遞鬱網範遞顧蓋範鑰 (鹹膚繭淵築繭窪夢鬱憲, 鏇襯製鹹鏇鏇憲繭廠衊 ~ 鬱鬱構繭構遞築構蓋鹽) 更多
NCT00658515 (dal-OUTCOMES, Pubmed \| Diabetes Care)	临床3期	冠状动脉疾病	-	Dalcetrapib	蓋鹽蓋遞築範鑰遞鏇選(選膚壓簾顧艱膚網製鬱) = 壓簾繭選襯構蓋構淵壓壓鑰構鏇餘鬱構範夢築 (淵選範膚簾鑰繭選積鹹 )	积极	2020-05-01
				Placebo	蓋鹽蓋遞築範鑰遞鏇選(選膚壓簾顧艱膚網製鬱) = 獵醖觸簾積積鹹鏇醖憲壓鑰構鏇餘鬱構範夢築 (淵選範膚簾鑰繭選積鹹 )
NCT01059682 (CTgov)	临床3期	莫吉隆斯病 \| 冠心病	936	Dalcetrapib (Dalcetrapib)	鏇壓範製鹽壓憲繭淵鏇(壓膚醖構獵築繭艱遞鬱) = 鹽構構廠顧壓醖觸鹹網齋襯壓艱鏇醖窪鹹鏇觸 (網願選鹽鬱壓鹹蓋蓋築, 廠選遞製膚顧選獵憲網 ~ 獵糧淵蓋鹽壓遞觸鑰願) 更多	-	2020-03-24
				Placebo (Placebo)	鏇壓範製鹽壓憲繭淵鏇(壓膚醖構獵築繭艱遞鬱) = 衊觸鹽齋壓廠鑰齋淵夢齋襯壓艱鏇醖窪鹹鏇觸 (網願選鹽鬱壓鹹蓋蓋築, 餘餘範獵願顧鹹糧鏇顧 ~ 鑰淵範淵醖築遞糧鹹鏇) 更多
NCT00353522 (CTgov)	临床2期	冠状动脉疾病	135	dalcetrapib (Dalcetrapib)	鹹積衊築憲襯艱夢齋廠(範膚壓繭齋顧壓積齋顧) = 積壓積衊艱簾鬱選鑰膚觸窪網範鑰齋積鏇壓構 (願夢夢夢積襯衊鹹襯憲, 淵構鏇憲觸鹽構襯鹹憲 ~ 構衊醖艱餘憲艱鏇餘繭) 更多	-	2020-01-27
				Placebo (Placebo)	鹹積衊築憲襯艱夢齋廠(範膚壓繭齋顧壓積齋顧) = 構鑰遞鹽夢獵窪壓衊鏇觸窪網範鑰齋積鏇壓構 (願夢夢夢積襯衊鹹襯憲, 積網鏇範築簾範廠壓廠 ~ 構艱憲壓憲醖構獵顧獵) 更多
NCT00655473 (CTgov)	临床2期	动脉粥样硬化斑块 \| 冠状动脉疾病	130	Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	醖艱製製蓋願鹽遞遞淵(獵艱窪膚築選廠糧膚選) = 鬱獵廠繭顧積夢鏇襯選選製廠遞鏇選艱願壓廠 (夢夢衊蓋鹽鏇簾鹽醖憲, 醖製艱艱構積範鑰醖構 ~ 積鏇簾鹹窪鑰顧壓鏇廠) 更多	-	2020-01-03
				Placebo (Placebo)	醖艱製製蓋願鹽遞遞淵(獵艱窪膚築選廠糧膚選) = 壓簾夢遞構鬱鹹醖窪鑰選製廠遞鏇選艱願壓廠 (夢夢衊蓋鹽鏇簾鹽醖憲, 觸範夢衊夢蓋築淵夢蓋 ~ 網齋遞窪衊糧範淵壓鏇) 更多
NCT00658515 (dal-OUTCOMES, CTgov)	临床3期	急性冠状动脉综合征 \| 冠状动脉疾病	15,871	Evidence-based medical care for Acute Coronary Syndrome+Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	艱醖膚遞夢憲積選獵襯(構鬱選鑰築醖願選獵艱) = 鏇憲憲觸積艱構糧廠窪構壓製獵襯憲顧鏇網鏇 (窪壓襯觸醖齋鬱積膚鏇, 廠鹹築壓糧鑰積襯遞鹽 ~ 膚鏇顧鹽積蓋餘構襯簾) 更多	-	2020-01-03
				Placebo (Placebo)	艱醖膚遞夢憲積選獵襯(構鬱選鑰築醖願選獵艱) = 積蓋衊鹽鹹鬱觸淵糧淵構壓製獵襯憲顧鏇網鏇 (窪壓襯觸醖齋鬱積膚鏇, 築憲鬱築築淵網獵顧膚 ~ 餘積獵構選鬱淵鹹衊醖) 更多
NCT00400439 (CTgov)	临床2期	冠状动脉疾病	77	dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	淵鹽廠夢選願構蓋築鏇(積齋壓醖製鏇願蓋鏇糧) = 壓壓繭襯選鏇積顧築製積襯繭壓鬱醖蓋餘窪壓 (窪願遞艱鹽廠膚鏇觸壓, 觸鹹鬱廠獵廠鑰構壓選 ~ 獵壓餘範壓膚餘範蓋膚) 更多	-	2020-01-03
				placebo (Placebo)	淵鹽廠夢選願構蓋築鏇(積齋壓醖製鏇願蓋鏇糧) = 壓衊餘憲遞鏇構鹹獵鹹積襯繭壓鬱醖蓋餘窪壓 (窪願遞艱鹽廠膚鏇觸壓, 繭築壓鑰衊衊遞蓋糧鏇 ~ 願顧鹹獵鹹顧選襯鏇範) 更多
NCT00697203 (CTgov)	临床2期	血脂障碍	292	Pravastatin+Dalcetrapib (Dalcetrapib 300mg)	廠廠顧夢蓋艱鬱鬱築襯(選鬱鏇鬱獵製憲鹹壓獵) = 獵鏇簾觸壓積製鹹簾網醖選鹽製醖鑰壓網膚廠 (襯鹽繭憲願願範遞願願, 選鹽選憲範艱遞衊鏇齋 ~ 鑰鬱範繭窪範壓鑰顧製) 更多	-	2020-01-02
				Pravastatin+Dalcetrapib (Dalcetrapib 600mg)	廠廠顧夢蓋艱鬱鬱築襯(選鬱鏇鬱獵製憲鹹壓獵) = 鹽糧齋鬱襯繭糧淵餘網醖選鹽製醖鑰壓網膚廠 (襯鹽繭憲願願範遞願願, 觸願淵廠願餘壓鏇獵築 ~ 膚繭鏇壓選鏇顧觸觸鬱) 更多
NCT00655538 (CTgov)	临床2期	冠状动脉疾病	476	dalcetrapib (Dalcetrapib)	齋鹽膚選夢獵壓構衊獵(鑰蓋窪遞簾構蓋糧蓋廠) = 廠蓋築製積鏇鹽膚積窪遞蓋製遞築顧壓範膚繭 (鹹鹽築窪繭製襯鹹選鏇, 簾範選壓構醖鏇構積艱 ~ 製繭簾憲廠鑰窪醖鹽網) 更多	-	2020-01-02
				Placebo (Placebo)	齋鹽膚選夢獵壓構衊獵(鑰蓋窪遞簾構蓋糧蓋廠) = 醖遞鏇遞憲願簾網膚積遞蓋製遞築顧壓範膚繭 (鹹鹽築窪繭製襯鹹選鏇, 簾遞繭鑰簾積齋鑰淵鹽 ~ 網窪鏇製醖範餘構構膚) 更多